## FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL						
OMB Number: 3235-0						
Estimated average burden						
hours per response	0.5					

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Typ															
1. Name and Address of Reporting Person * Beebe Katherine				2. Issuer Name and Ticker or Trading Symbol TITAN PHARMACEUTICALS INC [TTNP]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  X_ Director						
(Last) (First) (Middle) 400 OYSTER POINT BLVD, SUITE 505				3. Date of Earliest Transaction (Month/Day/Year) 02/10/2021											
(Street)				4. If Amendment, Date Original Filed(Month/Day/Year)											
SOUTH S	SAN FRAI	NCISCO, CA 94	080								in med by w	iore than One iv	eporting rerson		
(City) (State) (Zip)				Table I - Non-Derivative Securities Acqu					uired, I	nired, Disposed of, or Beneficially Owned					
1.Title of Security (Instr. 3)  2. Transaction Date (Month/Day/Yea		) any	tion Date, if	Code (Instr.	(.	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		5. Amount of Securi Owned Following R Transaction(s)			) F	Ownership	7. Nature of Indirect Beneficial		
					h/Day/Year)	Cod	le V A	(A) or Amount (D)		(Instr. 3 and 4)			o (	Direct (D) (or Indirect (I) (Instr. 4)	Ownership Instr. 4)
Reminder: R	Report on a se	eparate line for each	class of securities be	eneficiall	y owned dir	ectly or	Person in this		t require	ed to re	espond u		on contained form display		474 (9-02)
Reminder: R	Report on a se	eparate line for each		- Deriva	tive Securit	ies Acq	Person in this is a curre	form are no ntly valid O osed of, or Bo	t require MB cont	ed to re trol nu	espond u mber.				474 (9-02)
1. Title of Derivative Security (Instr. 3)	2. Conversion	3. Transaction	Table II - 3A. Deemed Execution Date, if	- Deriva (e.g., pu 4. Transac Code	tive Securit uts, calls, w. 5. Nun tion Deriva Securit ) Acquir	ies Acq arrants, ber of tive ies ed (A) oosed of	Person in this to a curre uired, Dispo options, co of Date Ext Expiration (Month/Date of the control of the con	form are no ntly valid O osed of, or Boundary of the new propertible security and Date	trequire MB conf eneficially curities)  7. Tit of Ur Secur	ed to retrol number of the and Anderlyin	espond u mber. ed Amount	8. Price of		To 10. Ownershiform of Derivativ Security: Direct (Dor Indirect)	11. Natur p of Indirec Beneficia Ownersh (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative	3. Transaction Date	Table II - 3A. Deemed Execution Date, if any	- Deriva (e.g., pu 4. Transac Code	tive Securit uts, calls, w. 5. Nun Deriva Securit ) Acquir or Disp (D) (Instr.	ies Acq arrants, ber of tive ies ed (A) oosed of	Person in this to a curre uired, Dispo options, co of Date Ext Expiration (Month/Date of the control of the con	form are nontly valid O seed of, or B nvertible sec ercisable and Date y/Year)  Expiration	trequire MB conf eneficially curities)  7. Tit of Ur Secur	ed to retrol number of the and Aderlyin rities: 3 and 4	espond u mber. ed Amount	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially Owned Following Reported	To 10. Ownershiform of Derivativ Security: Direct (Dor Indirect)	11. Natur p of Indirec Beneficia Ownersh (Instr. 4)

#### **Reporting Owners**

	Relationships				
Reporting Owner Name / Address	Director	10% Owner	Officer	Other	
Beebe Katherine 400 OYSTER POINT BLVD, SUITE 505 SOUTH SAN FRANCISCO, CA 94080	X		President and COO		

### **Signatures**

/S/ Kate Beebe Devarney	02/10/2021
**Signature of Reporting Person	Date

#### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The options vest as to 75,000 shares on August 10, 2021 with the balance to vest in equal monthly installments over the 18 months thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.